Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +35.94%
#3 Bedrock Bedrock +20.06%
#4 Cysic Cysic +18.33%
#5 Fabric Protocol Fabric Protocol +13.41%
#6 Nockchain Nockchain +11.94%
#7 Perle Perle +8.19%
#8 stake.link stake.link +8.12%
#9 Arowana Arowana +7.88%
#10 Cap Cap +7.72%
Coin of the day
EXOD EXOD
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Pascal Biosciences Inc. Pascal Biosciences Inc.

Pascal Biosciences Inc.

PSCBF
Classifica tra le azioni #37975
Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to... Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.
Prezzo delle azioni
$0.1
Ultima sincronizzazione: 2024-06-18
Capitalizzazione di mercato
$1.31M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Pascal Biosciences Inc. (PSCBF)

Categoria

Healthcare
Rapporto P/B per Pascal Biosciences Inc. (PSCBF)
Rapporto P/B al August 2026 TTM: 2.64
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Pascal Biosciences Inc., il rapporto P/B attuale (TTM) è 2.64. Alla fine del 2022, era pari a -1.43.
Storico del rapporto P/B per Pascal Biosciences Inc. da 2019 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
2026 (TTM) 2.64 127.72%
2023 1.16 -181.08%
2022 -1.43 7,479.37%
2021 -0.02 6,200.00%
2020 0.00 0.00%
2019 0.00 0.00%
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 137.04%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 140.33%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 37.57%
BE